Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

[Upstream administration of oral antiplatelet agents in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention].

Ferlini M, Mafrici A, Marzegalli M, Piccaluga E, Sponzilli C, Bramucci E, Visconti LO.

G Ital Cardiol (Rome). 2014 Feb;15(2):90-8. doi: 10.1714/1424.15778. Review. Italian.

PMID:
24625848
2.
3.

Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.

Capranzano P, Mehran R, Tamburino C, Stone GW, Dangas G.

Hosp Pract (1995). 2010 Nov;38(4):38-43. doi: 10.3810/hp.2010.11.338.

PMID:
21068525
4.

Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trial.

Mrdovic I, Savic L, Krljanac G, Asanin M, Cvetinovic N, Brdar N, Stojanovic M, Djuricic N, Stankovic S, Marinkovic J, Perunicic J.

J Interv Cardiol. 2013 Jun;26(3):221-7. doi: 10.1111/j.1540-8183.2013.12024.x. Epub 2013 Feb 4.

PMID:
23373620
5.

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.

Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G.

Circ Cardiovasc Interv. 2012 Dec;5(6):797-804. doi: 10.1161/CIRCINTERVENTIONS.112.972323. Epub 2012 Nov 20.

6.
8.

Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel.

Wouter Jukema J, Collet JP, De Luca L.

Curr Med Res Opin. 2012 Feb;28(2):203-11. doi: 10.1185/03007995.2011.651526. Epub 2012 Jan 19. Review.

PMID:
22181345
9.

Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.

Tanguay JF, Bell AD, Ackman ML, Bauer RD, Cartier R, Chan WS, Douketis J, Roussin A, Schnell G, Verma S, Wong G, Mehta SR; Canadian Cardiovascular Society.

Can J Cardiol. 2013 Nov;29(11):1334-45. doi: 10.1016/j.cjca.2013.07.001. Epub 2013 Aug 23. Review.

PMID:
23978596
10.

Updates in antiplatelet agents used in cardiovascular diseases.

Cheng JW.

J Cardiovasc Pharmacol Ther. 2013 Nov;18(6):514-24. doi: 10.1177/1074248413499971. Review.

PMID:
24213473
11.

Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials.

Sethi A, Bahekar A, Doshi H, Bhuriya R, Bedi U, Singh S, Khosla S.

Can J Cardiol. 2011 Sep-Oct;27(5):548-54. doi: 10.1016/j.cjca.2011.03.017. Epub 2011 Aug 25.

PMID:
21871775
12.

Effects of P2Y12 receptor inhibition in patients with ST-segment elevation myocardial infarction.

Alexopoulos D, Xanthopoulou I, Goudevenos J.

Am J Cardiol. 2014 Jun 15;113(12):2064-9. doi: 10.1016/j.amjcard.2014.03.053. Epub 2014 Apr 2. Review.

PMID:
24793666
13.

Antiplatelet effect of thienopyridine (clopidogrel or prasugrel) pretreatment in patients undergoing primary percutaneous intervention for ST elevation myocardial infarction.

Beigel R, Fefer P, Rosenberg N, Novikov I, Elian D, Fink N, Segev A, Guetta V, Hod H, Matetzky S.

Am J Cardiol. 2013 Nov 15;112(10):1551-6. doi: 10.1016/j.amjcard.2013.07.010. Epub 2013 Aug 22.

PMID:
23972349
14.

Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.

Motovska Z, Kala P.

Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001. Review.

PMID:
19281914
15.

Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.

Heestermans AA, Van Werkum JW, Hamm C, Dill T, Gosselink AT, De Boer MJ, Van Houwelingen G, Hoorntje JC, Koopmans PC, Ten Berg JM, Van 't Hof AW.

J Thromb Haemost. 2009 Oct;7(10):1612-8. doi: 10.1111/j.1538-7836.2009.03573.x. Epub 2009 Aug 11.

16.

Current management and quality of life of patients with acute coronary syndrome undergoing percutaneous coronary intervention in Greece: 12-Month results from antiplatelet therapy observational study II (APTOR II).

Pavlides G, Drossinos V, Dafni C, Altsitzoglou P, Antoniadis A, Manolis AS, Tsioufis C, Goudevenos I, Kochiadakis G, Alexopoulos D.

Hellenic J Cardiol. 2013 Jul-Aug;54(4):255-63.

17.
18.

Emergency percutaneous coronary intervention (PCI) for the care of patients with ST-elevation myocardial infarction (STEMI).

Morrison DA, Berman M, El-Amin O, McLaughlin RT, Bates ER.

Minerva Cardioangiol. 2007 Oct;55(5):593-623. Review.

PMID:
17912165
19.

A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Dasbiswas A, Rao MS, Babu PR, Vijayvergiya R, Nayak R, Dani S, Tyagi S, Hiremath S, Patel T, Alexander T, Prakash VS, Singh DP, Yadav MK, Pathak K, Srivastava A.

J Assoc Physicians India. 2013 Feb;61(2):114-6, 126.

PMID:
24471250
20.

Optimizing platelet P2Y12 inhibition for patients undergoing PCI.

Steinhubl S, Roe MT.

Cardiovasc Drug Rev. 2007 Summer;25(2):188-203. Review. Erratum in: Cardiovasc Drug Rev. 2007 Autumn;25(3):299.

PMID:
17614940

Supplemental Content

Support Center